A systems biology approach identifies effective tumor-stroma common targets for oral squamous cell carcinoma

Cancer Research

Volumn 74, Issue 8, 2014, Pages 2306-2315

  Meng, Wenxia ^a,e   Wu, Yun ^a,d   He, Xin ^a,f   Liu, Chuanxia ^a   Gao, Qinghong ^c   Ge, Lin ^a   Wu, Lanyan ^b   Liu, Ying ^a   Guo, Yiqing ^a   Li, Xiaoyu ^a   Liu, Yurong ^a   Chen, Sixiu ^a   Kong, Xiangli ^a   Liang, Zhi ^g   Zhou, Hongmei ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c Department of Oral Oncology ^*  (China)

^d CHONGQING MEDICAL UNIVERSITY   (China)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

^f ANHUI MEDICAL UNIVERSITY   (China)

^g UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; STROMA; SYSTEMS BIOLOGY;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL COMMUNICATION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FIBROBLASTS; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, INBRED BALB C; MOUTH NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; STROMAL CELLS; TRANSFECTION;

EID: 84899580916     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2275     Document Type: Article

References (41)

1. Bagley RG. The Tum or microenvironment. New York: Springer; 2010.
2. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6: 392-401.
3. Ostman A, Augsten M. Cancer-Associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev 2009;19:67-73.
4. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res 2011;1:482-97.
5. Sawyers C. Targeted cancer therapy. Nature 2004;432:294-7.
6. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012;30:679-92.
7. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004;4:839-49.
8. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005;7:513-520.
9. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011;17:320-329.
10. Strausberg RL, Simpson AJ, Wooster R. Sequence-based cancer genomics: progress, lessons and opportunities. Nat Rev Genet 2003; 4:409-418.
11. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R. A census of human cancer genes. Nat Rev Cancer 2004;4:177-183.
12. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 2008;322:881-888.
13. Wang E, Lenferink A, O'Connor-McCourt M. Cancer systems biology: exploring cancer-Associated genes on cellular networks. Cell Mol Life Sci 2007;64:1752-1762.
14. Pujana MA, Han JD, Starita LM, Stevens KN, Tewari M, Ahn JS. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 2007;39:1338-1349.
15. Chuang HY, Lee E, Liu YT, Lee D, Ideker T. Network-based classification of breast cancer metastasis. Mol Syst Biol 2007;3:140.
16. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
17. Lu Y, Yijun Yi, Pengyuan Liu, Weidong Wen, Michael James, Daolong Wang. Common human cancer genes discovered by integrated geneexpression analysis. PLoS One 2007;11:e1149.
18. Kuriakose MA, Chen WT, He ZM, Sikora AG, Zhang P, Zhang ZY. Selection and validation of differentially expressed genes in head and neck cancer. Cell Mol Life Sci 2004;61:1372-1383.
19. Toruner GA, Ulger C, Alkan M, Galante AT, Rinaggio J, Wilk R. Association between gene expression profile and tumor invasion in oral squamous cell carcinoma. Cancer Genet Cytogenet 2004;154: 27-35.
20. Shimizu S, Tsukada J, Sugimoto T, Kikkawa N, Sasaki K, Chazono H. Identification of a novel therapeutic target for head and neck squamous cell carcinomas: a role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathway. Int J Cancer 2008;123:1816-1823.
21. Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J. The DAVID Gene Functional Classification Tool: a novel biological modulecentric algorithm to functionally analyze large gene lists. Genome Biol 2007;8:R183.
22. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-2504.
23. Spirin V, Mirny LA. Protein complexes and functional modules in molecular networks. Proc Natl Acad Sci U S A 2003;100:12123-8.
24. Bork P, Jensen LJ, von Mering C, Ramani AK, Lee I, Marcotte EM. Protein interaction networks from yeast to human. Curr Opin Struct Biol 2004;14:292-299.
25. Meng WX, Xia Q,WuL, Chen S, He X, Zhang L. Downregulation of TGFbeta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-Associated fibroblasts. BMC Cancer 2011;11:88-101.
26. Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res 2007;67:1090-1098.
27. Gatza CE, Oh SY, Blobe GC. Roles for the type III TGF-b receptor in human cancer. Cell Signal 2010;22:1163-1174.
28. Mythreye K, Blobe GC. The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-Arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci U S A 2009;106: 8221-6.
29. Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM. Type III TGF-b receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest 2013;123:3925-40.
30. Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat Rev Cancer 2004;4:227-235.
31. Crawford Y, Ferrara N. Tumor and stromal pathways mediating refractoriness/ resistance to anti-Angiogenic therapies. Trends Pharmacol Sci 2009;30:624-30.
32. Correia AL, Bissell MJ. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat 2012;15:39-49.
33. Howell A, Landberg G, Bergh J. Breast tumour stroma is a prognostic indicator and target for therapy. Breast Cancer Res 2009;11:S16.
34. Udagawa T, Wood M. Tumor-stromal cell interactions and opportunities for therapeutic intervention. Curr Opin Pharmacol 2010;10: 369-374.
35. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346-52.
36. Kalev P, Simicek M, Vazquez I, Munck S, Chen L, Soin T, et al. Loss of PPP2R2A Inhibits Homologous Recombination DNA Repair and Predicts Tumor Sensitivity to PARP Inhibition. Cancer Res 2012;72: 6414-24.
37. Barabasi AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004;5:101-113.
38. Azmi AS. Systems biology in cancer research and drug discovery. New York, USA: Springer; 2010.
39. Zhou Q, Lv H, Mazloom AR, Xu H, Ma'ayan A, Gallo JM. Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts. J Pharmacol Exp Ther 2012;343: 509-519.
40. Hartwell LH, Hopfield JJ, Leibler S, Murray AW. From molecular to modular cell biology. Nature 1999;402:47-52.
41. Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks. Nature 2000;406:378-382.